J
J-Pharma
Japan · Biotech
J-Pharma develops drugs that target SLC transporters, with programmes in cancer and autoimmune diseases.
Product
J-Pharma is a Japanese drug developer focused on SLC transporters, proteins involved in moving substances across cell membranes. Its research centres on LAT1, a transporter involved in amino-acid uptake and expressed at high levels in many cancer cells.
Its pipeline includes nanvuranlat, also known as JPH203, a small-molecule LAT1 inhibitor being studied for biliary tract cancer. The company is conducting the global Phase 3 Beacon-BTC trial and also works on treatments for autoimmune diseases.
Funding history
1 round · 1 with disclosed amounts| Announced | Round | Amount | Investors |
|---|---|---|---|
| AMED GRiT grant | ≤¥1.5B | Japan Agency for Medical Research and Development (AMED) — Participant |